Animal models of sepsis and its complications

Kidney International

Volumn 74, Issue 8, 2008, Pages 991-993

  Fink, Mitchell P ^a,b,c  

^a Logical Therapeutics Inc   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; VASCULOTROPIN RECEPTOR 1;

ANTIINFLAMMATORY ACTIVITY; DRUG MECHANISM; KIDNEY DYSFUNCTION; KIDNEY INJURY; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; SEPSIS;

EID: 53049091405     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.442     Document Type: Note

References (17)

1. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
3. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
4. Bernard GR, Vincent J-L, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
5. Costa V, Brophy JM. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiol 2007; 7: 5.
6. Castelli EE, Culley CM, Fink MP. Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. Pharmacotherapy 2005; 25: 1147-1150.
7. Kanji S, Perreault MM, Chant C et al. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 2007; 33: 517-523.
8. Mackenzie AF. Activated protein C: do more survive? Intensive Care Med 2005; 31: 1624-1626.
9. Kellum JA, Kong L, Fink MP et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-1663.
10. Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818.
11. Bagshaw SM, Uchino S, Bellomo R et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007; 2: 431-439.
12. Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care 2008; 12: R47.
13. Oppert M, Engel C, Brunkhorst FM et al. Acute renal failure in patients with severe sepsis and septic shock a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008; 23: 904-909.
14. Rasmussen HH, Ibels LS. Acute renal failure. Multivariate analysis of causes and risk factors. Am J Med 1982; 73: 211-218.
15. Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994; 78: 143-149.
16. Doi K, Leelahavanichkul A, Hu X et al. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int 2008; 74: 1017-1025.
17. Miyaji T, Hu X, Yuen PST et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64: 1620-1631.